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Aim: To evaluate the differences in treatment response and the impact on survival with both
oral  agents (UFT and Capecitabine) as neoadjuvant chemotherapy administered concomi-
tantly with radiotherapy.
Background: There are still no studies comparing the use of neoadjuvant oral chemotherapy
either with UFT plus Folinic acid or Capecitabine concomitant with radiotherapy in locally
advanced rectal cancer (LARC).
Materials and methods: A set of 112 patients with LARC were treated preoperatively. GROUP
1  – 61 patients underwent concomitant oral chemotherapy with Capecitabine (825 mg/m2
twice daily). GROUP 2 – 51 patients submitted to concomitant oral chemotherapy with UFT
(300  mg/m2/d) + Folinic acid (90 mg/d) and radiotherapy. 57.1% of patients were submitted to
adjuvant chemotherapy.
Results: GROUP 1: acute toxicity – 80.3%; pathological complete response (pCR) – 10.5%; tumor
downstaging (TD) – 49.1%; nodal downstaging (ND) – 76.5%; loco-regional response (LRR) –
71.9%;  toxicity to adjuvant chemotherapy – 75%. GROUP 2: acute toxicity – 80.4%; pCR – 28%;
TD  – 62%; ND – 75.6%; LRR – 78%; toxicity to adjuvant chemotherapy – 56%. There was  no
difference in survival nor loco-regional control between the groups.
Conclusions: Patients treated with neoadjuvant oral UFT + Folinic acid had a higher rate of
pathologic complete response than patients treated with Capecitabine concomitant withradiotherapy. There were no differences in downstaging, LRR, toxicity, survival or loco-
regional control between both groups. There was a trend to a higher rate of toxicity to
adjuvant chemotherapy in the Capecitabine group.
©  2012 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All∗ Corresponding author at: Hospitais da Universidade de Coimbra, Prac
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.  Background
he neoadjuvant use of CT and RT in locally advanced rectal
ancer (LARC) allows a higher rate of resectability asso-
iated to a tumor and nodal downstaging.1 Concomitant
eoadjuvant 5-FU CT + RT provides a pathological complete
esponse (pCR) in 8–27% of patients and is associated to an
ncreased local control.1–13 Theoretically, oral ﬂuoropyrimi-
ines are suitable to replace 5-FU protracted infusion and
void catheter-related complications, such as infection, sep-
is, pneumothorax, thrombosis and blockage.14,15 In general,
atients tend to prefer oral treatments, provided that efﬁcacy
s not compromised.16
UFT is an oral combination of uracil and tegafur in a
xed 1:4 molar ratio.17 Tegafur is a prodrug converted to 5-
U by the hepatic microsomal system following intestinal
bsorption. Uracil competitively inhibits dihydropyrimidine
ehydrogenase, the chief catabolic enzyme of 5-FU, which
esults in elevated and maintained concentrations of 5-FU
or a prolonged period and thus simulates a continuous infu-
ion of 5-FU to improve the absorption and bioavailability of
egafur.18–20
In preclinical experiments, leucovorin (LV) has been com-
ined with UFT in an attempt to enhance antitumor activity.21
n patients with advanced colorectal cancer, the combina-
ion of UFT and oral LV produced objective response rates
anging from 25% to 42%.22 Preliminary results from two
arge randomized studies in patients with metastatic colorec-
al cancer suggested that patients treated with UFT/LV and
hose receiving bolus intravenous 5-FU/LV may have an equiv-
lent response and survival rate.22,23 In the adjuvant setting,
apanese investigators compared postoperative UFT to surgery
lone; UFT led to a signiﬁcantly improved 4-year disease-
ree survival, particularly in patients with rectal cancer.24 Like
nfusional 5-FU, UFT is generally well tolerated, with diarrhea,
ausea, and anorexia being the most frequent adverse effects.
n reported trials, grade 3 or 4 diarrhea occurred in 4% to 21% of
atients.18,22,23 UFT is not associated with signiﬁcant myelo-
uppression, mucositis, hand–foot syndrome, or alopecia.
Pharmacokinetic studies have shown that 5-FU plasma
evels in patients receiving protracted infusions of 5-FU are
imilar to those found in patients receiving oral UFT, although
eak levels of 5-FU are higher with UFT.18 Although a large
umber of patients have received UFT plus oral LV as adjuvant
hemotherapy or to treat metastatic disease, there is little data
n the use of UFT/LV with radiation therapy in patients with
ectal cancer.
Capecitabine is a ﬂuoropyrimidine carbamate prodrug of
-FU designed to generate 5-ﬂurouracil (5-FU) preferentially
n tumor cells25 as concentration of the key enzyme thymi-
ine phosphorylase is higher in tumor cells compared with
ormal tissue. In preclinical studies, irradiation with thymi-
ine phosphorylase was found to be upregulated in tumor
issue resulting in a selective synergistic effect of Capecitabine
n radiotherapy.26–28 Capecitabine is administered daily to
29imic  a continuous infusion of 5-FU. This continuous reg-
men is likely to have a more  constant cytotoxic action,
hereby limiting tumor regrowth. The side-effect proﬁle of
apecitabine is similar to that observed when 5-FU is giventherapy 1 7 ( 2 0 1 2 ) 376–383 377
as a protracted infusion and consists mainly in diarrhea. The
dose-limiting toxicity is the hand–foot syndrome, occurring
as the Capecitabine dose reaches 1000 mg/m2 b.i.d. Other tox-
icities were generally mild to moderate.30,31
A phase I study on rectal cancer (Dunst) deﬁned the
recommended dose of Capecitabine to be 825 mg/m2 b.i.d.,
administered 7 d/week during a conventional RT period of
about 6 weeks for preoperative therapy in LARC.32
2.  Aim
As the standard schedule of preoperative CT + RT for rectal
cancer remains to be established and given the convenience
of oral prodrugs vs.  5-FU and the lack of studies comparing
different kinds of oral chemotherapy, we wanted to compare
the therapeutic response to oral chemotherapy either with
UFT/Folinic acid (FA) or Capecitabine combined with preop-
erative RT in patients with stages II–III rectal cancer. Toxicity
and survival were also analyzed for those groups of patients, as
well as the relationship between pathological response, tumor
and nodal downstaging, loco-regional response and survival.
3.  Materials  and  methods
3.1.  Patients
We  prospectively analyzed 112 patients with LARC treated
with neoadjuvant oral chemotherapy and radiation from
January 2003 to September 2009. Patients were divided into
2 groups. GROUP 1: consisting of 61 patients who  were treated
with RT and concomitant oral CT with Capecitabine. GROUP
2: consisting of 51 patients, submitted to RT and concomitant
oral CT with UFT plus FA. Patients’ characteristics correspond-
ing to the different groups are described in Table 1.
3.2.  Neoadjuvant  chemotherapy
GROUP 1 was treated with RT concomitant to oral CT with
Capecitabine 825 mg/m2 twice daily for the duration of RT,
7 d/week (61 patients). GROUP 2 was treated with RT concomi-
tant to oral CT with UFT at 300 mg/m2/d together with Folinic
acid 90 mg/d (51 patients), in 3 fractions/d, 5 d/week (Monday
through Friday, with the weekend as a rest period).
3.3.  Neoadjuvant  radiotherapy
The patient’s prone position was recommended, and a belly
board immobilization device was used. A pelvic CT scan
in the treatment position was performed in all patients,
from L5-S1 to 2 cm above the anus. All patients underwent
three-dimensional treatment planning. CT scan was used to
deﬁne gross tumor volume (GTV). Clinical target volume (CTV)
included the GTV + 2 cm in all directions, perirectal, internal
iliac and presacral nodes up to the promontory; for T4 (seminal
vesicles, prostate, vagina or uterus involvement) external iliac
nodes were also included; the inguinal areas were irradiated
in those patients who had invasion of the anal canal.33,34
The planning target volume (PTV) was deﬁned as
CTV + 1 cm margin. The treatment was delivered through
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Table 1 – Comparison of patients’ characteristics and
surgical status between patients treated with
Capecitabine and UFT + Folinic acid.
Patients’
characteristics
Capecitabine
(n = 61)
UFT + LV
(n = 51)
p  value
Age (years)
Min–Max 38–82 35–82
Median 64 64
Sex
Male 37 (60.7%) 38 (74.5%)
0.158
Female 24 (39.3%) 13 (25.5%)
Karnofsky
100% 35 (57.4%) 38 (74.5%)
0.12990% 24 (39.3%) 11 (21.6%)
80% 2 (3.3%) 2 (3.9%)
Distance to anal margin
0–5 cm 36 (59%) 28 (54.9%)
0.704
6–11 cm 25 (41%) 23 (45.1%)
Imaging staging
(CT/MRI scan)
18%/82% 5.9%/92.2% 0.090
Clinical staging
cT2 9 (14.8%) 2 (3.9%)
0.144cT3 48 (78.3%) 44 (86.3%)
cT4 4 (6.6%) 5 (9.8%)
cN0 6 (9.8%) 5 (9.8%)
1.0
cN+ 55 (90.2%) 46 (90.2%)
Timing to
surgery
(median)
7  weeks 7 weeks
Surgical resection
R0 51 (83.7%) 47 (92.1%)
4.1.1.  Preoperative  treatment0.664
R1 6 (9.8%) 3 (5.9%)
Unresectable 3 (4.9%) 1 (2%)
Non operated 1 (1.6%) –
three to four ﬁelds via the isocenter technique, shaped with
multileaf collimator, and high-energy photons of 18 MV. The
total dose administered was 50.4 Gy with conventional frac-
tionation of 1.8 Gy/d, 5 d/week. The prescribed dose was
speciﬁed at the International Commission on Radiation Units
and Measurements point and isodose distribution to the PTV
(95–107%).
3.4. Surgery
Surgery was performed by specialized surgeons of the Surgi-
cal Department of our Institution. Patients were scheduled for
surgery between the sixth and eighth week following the con-
clusion of the neoadjuvant therapy and were treated with a
total mesorectum excision and a rectal anterior resection was
done whenever possible.
3.5. Toxicity  assessment
Toxicity was evaluated weekly in each patient using Common
Terminology Criteria for Adverse Events vs. 3.0 (CTCAE).35 A
complete blood count and biochemical tests were obtained
weekly.
3.6.  Deﬁnition  of  responseEvaluation of response to preoperative treatment was deﬁned
pathologically. Resected tumors were classiﬁed pathologicallyiotherapy 1 7 ( 2 0 1 2 ) 376–383
according to the TNM staging system, version 6.36 Tumor
downstaging was deﬁned as postoperative ypT stage lower
than preradiotherapy clinical cT stage. Nodal downstaging
was deﬁned as postoperative ypN stage lower than preradio-
therapy clinical cN stage. Loco-regional response was deﬁned
as a downstaging from cTN to pTN. A pathological complete
response (pCR) was considered when there were no residual
malignant cells.
3.7.  Adjuvant  treatment
After surgery, adjuvant CT was given to patients who
were considered by the treating physician to potentially
beneﬁt from postoperative therapy (64 patients). Adjuvant
chemotherapy was selected according to the previous neoad-
juvant CT scheme administered concurrently with RT. Patients
previously treated with UFT in the neoadjuvant setting, were
treated with UFT in the adjuvant setting as well. The same
applied to patients treated with Capecitabine in the neoadju-
vant setting who also were treated with Capecitabine in the
adjuvant setting. In those cases, where there was a tumor
or nodal upstaging, as long as tolerated by the patient, an
Oxaliplatin-based chemotherapy was administered. The pro-
tocols of adjuvant CT used were UFT (42.2%), Capecitabine
(37.5%), CAPOX (10.9%), FOLFOX (3.1%), or others (4.7%).
The majority of patients from GROUP 1 were treated with
Capecitabine and the majority from GROUP 2 with UFT.
3.8. Follow-up
Following the conclusion of treatment, patients had outpa-
tient clinic appointments every 3 months for the ﬁrst 2 years,
and then every 6 months.
3.9.  Patterns-of-failure  analysis  and  survival
Loco-regional failure was deﬁned as a relapse in the pelvis
(tumor bed, pelvic nodes, anastomosis, or perineal scar). Fail-
ure at distance was deﬁned as relapse in any other site. OS,
PFS, and loco-regional control (LRC) were calculated from the
date of the beginning of treatment.
3.10. Statistical  considerations
Statistical analyses were performed using the SPSS 16.0 sta-
tistical package. The p-value was calculated by the chi-square
test to compare variables. OS, PFS and LRC probabilities were
calculated by the Kaplan–Meier method, and differences were
evaluated by the log-rank test. A two-sided p-value of <0.05 was
considered statistically signiﬁcant.
4. Results
4.1.  Toxicity  and  treatment  adherenceOverall, preoperative therapies were well tolerated and the
most commonly reported toxicities are shown in Table 2. In
GROUP 1, 80.3% of patients presented acute toxicity, while only
reports of practical oncology and radio
Table 2 – Neoadjuvant chemoradiotherapy acute
toxicities incidence. CTCAE (v. 3.0).
Acute toxicity
(%)
GROUP 1 GROUP 2
Grades
1–2
Grades
3–4
Grades
1–2
Grades
3–4
Diarrhea 26.2 8.2 29.4 2
Vomiting 4.9 2
Radiodermatitis 50.8 4.9 58.8 3.9
Hand–foot
syndrome
11.5
Hematologic 13.1 13.7 3.9
Others 13.1 11.8
Table 3 – Incidence of postoperative complications.
Postoperative
complications
GROUP 1 (n = 57) GROUP 2 (n = 50)
Suture dehiscence 4 (7%) 7 (14%)
Sub-
occlusion/occlusion
4 (7%) 2 (4%)
Fistula 4 (7%) 1 (2%)
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OS was of 76.6% with a p value of 0.063.
Comparing GROUP 1 and GROUP 2, we realized that there
was no difference in 5-year OS (81.8% vs. 80.7%, p = 0.613) or inInfection 11(19.3%) 14 (28%)
 (11.5%) had grades 3–4 toxicity. GROUP 2 showed an acute
oxicity in 80.4% of patients, 4 of which (7.8%) were grades
–4. There was no signiﬁcant difference related to acute tox-
city (p = 1.0) or grades 3–4 acute toxicity (p = 0.751) among the
wo groups.
.1.2.  At  surgery
he median time interval between the end of RT and surgery
as 7 weeks. A complete resection was done in the majority
f patients. One patient was not operated due to intercurrent
llness (Table 1). There was no statistical difference in postop-
rative complications between the two groups (42.1% vs. 42%;
 = 1.0). The main postoperative complications are described
n Table 3. One patient died postoperatively due to pulmonary
hromboembolism.
Table 4 – Adjuvant CT acute toxicities incidence.
Adjuvant CT toxicities
CTCAE (v. 3.0)
GROUP 1 
Grades 1–2 Gr
Diarrhea – 2
Vomiting 1 (3.7%) –
Nausea 1 (3.7%) –
Anemia 16 (59.3%) –
Neutropenia 8 (29.6%) 1
Thrombocytopenia 6 (22.2%) –
Paresthesia 5 (18.5%) –
Hand–foot syndrome 2 (7.4%) 6
Weight loss 1 (3.7%) –
Bilirrubin – 1
Transaminases – –
Renal – –
Asthenia 1 (3.7%) –
Anorexia – –therapy 1 7 ( 2 0 1 2 ) 376–383 379
4.1.3.  Postoperative  treatment
Of the 107 patients submitted to radical surgery and who  were
candidates for adjuvant CT, only 59.8% received the proposed
treatment (36 patients from GROUP 1 and 28 patients from
GROUP 2). The majority of patients from GROUP 1 were treated
with Capecitabine (63.9%) and the majority of patients from
GROUP 2 were administered UFT + FA (92.9%) as adjuvant CT.
There was a trend for higher toxicity incidence in the
Capecitabine group than in UFT + FA group, although it was not
statistically signiﬁcant (75% vs.50%, p = 0.065). The respective
toxicities are described in Table 4.
The main reason why the 43 patients did not receive adju-
vant CT was postoperative complications (53.5%), 16.3% of
patients did not undergo adjuvant CT because of pCR and
pT2N0M0, 9.3% due to disease progression and 4.6% were not
referred to a medical oncology consult.
4.2.  Treatment  response
We  found a statistically signiﬁcant higher pCR in the group
of patients treated with oral UFT/FA + RT when compared to
patients who were treated with oral Capecitabine + RT (28%
vs. 10.5%, p = 0.026). Tumor downstaging was also higher in
GROUP 2 although this difference was not statistically sig-
niﬁcant (62% vs. 49.1%, p = 0.243). There was no difference
between both groups either in nodal downstaging (p = 1.0) or
in loco-regional response (p = 0.510) (Table 5).
With a median follow-up time of 30 months (5–91 months),
the global 5-year PFS was 71.5%, global 5-year OS was 80.5%
and LRC was of 94.7%. Of those, 5 patients who  had loco-
regional recurrence, 2 of them had been submitted to an R1
resection, 2 had distant recurrence, 1 had interrupted RT due
to sub-occlusive disease.
Considering our patients as a whole, we  noted that patients
with pCR had a 5-year OS of 100% while in those without pCRLRC (94.5% vs. 95.4%, p = 0.908), respectively. PFS was superior
GROUP 2
ades 3–4 Grades 1–2 Grades 3–4
 (7.4%) 1 (7.1%) 3 (21.4%)
 1 (7.1%) 1 (7.1%)
 1 (7.1%) 1 (7.1%)
 5 (35.7%) 1 (7.1%)
 (3.7%) 6 (42.9%) –
 2 (14.3%) –
 – –
 (22.2%) – –
 – –
 (3.7%) – –
 3 (21.4%) –
 1 (7.1%) 2 (14.3%)
 1 (7.1%) –
 1 (7.1%) –
380  reports of practical oncology and rad
Table 5 – Therapeutic response to neoadjuvant
treatment.
GROUP 1
(n = 57)
GROUP 2
(n = 50)
p value
Pathologic complete
response
10.5%  28% 0.026
Tumor downstaging 49.1% 62% 0.243
Nodal downstaging 76.5% 75.6% 1.00
Loco-regional
response
71.9% 78% 0.510
in GROUP 1 although without statistical signiﬁcance (75.2% vs.
68.2%, p = 0.258).
When we  analyzed the impact of each treatment on OS,
PFS or LRC, we found that the type of combined neoadju-
vant treatment prescribed was not determinant for survival in
any of the patients’ subgroups, whether they had pathological
complete response, tumor downstaging, nodal downstaging or
loco-regional response (Table 6).
5.  Discussion  and  conclusions
Neoadjuvant pelvic RT combined with CT should be regarded
as the standard treatment for stages II and III rectal can-
cer, leading to a higher loco-regional tumor control, tumor
downstaging and improved resectability not altering treat-
ment compliance.3,12,37–39 Preoperative RT with continuous i.v.
5-FU infusion has the biologic advantage of prolonging tumor
cells exposure to 5-FU and improving antitumor activity, how-
ever, its disadvantages include the requirement of a central
venous access with potential complications, such as bleeding,
thrombosis, infection and pneumothorax.40 Oral CT mimics
the pharmacokinetics of continuous 5-FU infusion and avoids
technical barriers of i.v. infusion with the advantage of conve-
nience. Oral ﬂuoropyrimidines, such as UFT and Capecitabine,
constitute an attractive alternative.
Although there are some studies comparing infusional
preoperative chemoradiotherapy with oral neoadjuvant
chemoradiotherapy either with Capecitabine or UFT,7,10 there
is not yet a single randomized study comparing the results of
both of these modalities of oral neoadjuvant chemotherapy
along with radiotherapy. Hence, we thought it worthwhile
to perform this single-institution prospective study, even
though it is not a randomized trial.
The majority of studies usually report pCR, tumor
downstaging and nodal downstaging as early endpoints of
Table 6 – Impact of treatment response on survival.
OS 
5-Year p v
Pathologic complete response GROUP 1 100%
1
GROUP 2 100% 
Tumor downstaging GROUP  1 87.1%
0
GROUP 2 100% 
Nodal downstaging GROUP  1 82.2%
0
GROUP 2 90% 
Loco-regional response GROUP 1 83.5%
0
GROUP 2 91.4% iotherapy 1 7 ( 2 0 1 2 ) 376–383
neoadjuvant chemoradiotherapy. The pCR appears to be asso-
ciated in some non-randomized studies with improvement
on PFS.8,41,42 It has been shown in one randomized trial that
the time interval between RT and surgery inﬂuences the
degree of downstaging, with 10% of patients operated within 2
weeks of RT experiencing pathological downstaging compared
to 26% of patients operated 6–8 weeks after RT (p = 0.005).43
Many studies have shown that neoadjuvant CT+RT signiﬁ-
cantly increases the rate of pCR, as well as nodal and tumor
downstaging,2–13 however, none of them have compared these
results between different modalities of oral chemotherapy.
Analyzing our set of patients we veriﬁed a signiﬁcantly bet-
ter pCR rate (p = 0.026) in the group of patients treated with
neoadjuvant oral UFT/FA with concomitant RT (28%) compar-
ing with patients treated with oral Capecitabine + RT (10.5%)
and tumor downstaging, although not signiﬁcant (p = 0.243),
was also higher in GROUP 2. There were no differences
in nodal downstaging (p = 1.00) and loco-regional response
rates (p = 0.510) between both groups of patients. The overall
response rates were similar to those reported in several other
studies,2,4–7,10,13,44,45 with the exception of pCR rate in patients
treated with neoadjuvant UFT/LV CT + RT that were higher
than those reported in former studies (Table 7). The patient’s
characteristics, neoadjuvant therapy acute toxicity and post-
operative complications were identical in both groups.
The most recently published article by the Korean Radia-
tion Oncology Group (KROG 09-01) collected clinical data for
333 LARC patients with ypT0 following preoperative CRT and
curative radical resections and they observed that even after
total regression of primary tumor, ypT0N0 patients had favor-
able long-term outcomes with a 5-year DFS and OS of 88.5%
and 94.8%, respectively, whereas ypT0N+ patients had a poor
prognosis (5-year DFS and OS of 45.2% and 72.8%, respectively,
p < 0.001).46
Maas et al. have recently47 evaluated the long-term out-
come in patients with pCR after CT + RT for rectal cancer and
have concluded that patients with pCR have a better long-term
outcome than those without it. They stated that pCR might be
indicative of a prognostically favorable biological tumor pro-
ﬁle with lower propensity for local or distant recurrence and
improved survival.
The Gastro-Intestinal Working Group of the Italian Asso-
ciation of Radiation Oncology analyzed retrospectively 566
patients with LARC achieving pCR after neoadjuvant therapy
and they veriﬁed that this favorable group of patients had a
very low rate of local recurrence (1.2%) and a favorable clinical
PFS LRC
alue 5-Year p value 5-Year p value
.0
66.7%
0.665
100%
1.0
79.6% 100%
.118
83.5%
0.664
100%
1.0
86.4% 100%
.870
75%
0.695
94.9%
0.684
72.8% 96.8%
.972
76.3%
0.923
95.1%
0.624
77.4% 97.2%
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Table 7 – Neoadjuvant chemoradiotherapy results (2, 4–7, 10, 13, 44, 45).
Authors No. RT CT Downstaging, T (%) Downstaging, N (%) pCR (%)
De Paoli [4] 53 50.4 C 57 78 24
Krishnan [5] 54 52.5 C 51 52 18
Kim [6] 95 50.4 C 57 69 12
Korkolis [44] 30 50.4 C 75 53 23
Kim [10]
145
50.4
5FU,  L – – 11.3
133 C – – 16.1
De la Torre [7]
77
45–50.4
5-FU  43.3 25 13.2
78 UFT, L 59.2  23.7 13.2
Fernandez-Martos [13] 94 45 UFT 54 –  15
Feliu [2] 41 50.4  UFT, L 61 – 15
Wang [45] 65  45 UFT, L 75 – 25
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PC, Capecitabine; L, leucovorin.
utcome independent of the neoadjuvant CT schedule used,
chieving a 5-year PFS of 84.7% and 5-year OS of 91.6%. In
uch a group of patients, the use of postoperative CT could be
ery debatable. Conversely, the subset of patients older than
0 years, with cStage III and treated with a radiation dose of
5 Gy or less experienced a relatively worse prognosis, even
fter achieving ypCR. The prognosis of the high-risk group
f patients compares with the outcome of a non-selected
opulation.48
Conde et al.42 also found a better PFS in those patients who
ad pCR (100% vs. 62%, p = 0.023). When considering only those
atients cT3-4 who  had downstaging to ypT0-2, they found a
igniﬁcantly better LRC (100% vs. 89, p = 0.027), PFS (88% vs.
3%, p = 0.003) and OS (89% vs. 77%, p = 0.048).
Kim et al. also showed excellent oncologic outcomes in
atients with pCR, with the pathologic N stage being the most
mportant factor for oncologic outcomes.49 Another study also
eriﬁed that pCR or intermediate response was related to an
mproved PFS after CT + RT.50 Julio Garcia-Aguilar et al. ana-
yzed a group of 168 patients treated with CT + RT and showed
 5-year LRC of 95%, an OS of 68% and a PFS of 95.2% in patients
ho  had pCR and 55.4% in patients without pCR. Their study
uggested that a pCR to CT + RT is a favorable prognostic factor
n patients with LARC.51
Valentini et al.41 demonstrated that, after preoperative
T + RT, clinical response and the tumor and nodal pathologic
ownstaging are closely related to improved outcome. Indeed,
atients with tumor downstaging had a 5-year local control of
7.8%, a PFS of 73.1% and an OS of 82.9%, while those who had
o tumor downstaging had a local control of 70.5%, a PFS of
7.2% and an OS of 60.9%. Those patients with nodal down-
taging also had better 5-year local control (84.3%) rate, PFS
67.1%) and OS (74.3%) than those who  did not have nodal
ownstaging (72%, 42.2% and 56.1%, respectively).
On the other hand, Pucciarelli et al. did not ﬁnd statis-
ically signiﬁcant differences for PFS and OS on comparing
he actuarial survival curves of patients with different tumor
esponses to preoperative treatment, whether evaluated as
umor regression grade or as pTNM stage.52
In our study we  observed a trend to a higher OS in those
atients who had pCR (p = 0.063), which converges to those
esults referred in literature. If we look into the impact of pCR
n the outcome in each group of patients we  verify that OS,
FS and LRC were similar in the two groups of patients. One ofthe reasons that might explain this lack of evidence is the low
absolute number of patients who actually had pCR (GROUP 1:
6 patients; GROUP 2: 14 patients).
The global 5-year LRC, PFS and OS were 94.5%, 75.2%
and 81.8%, respectively. There were no differences in sur-
vival between GROUP 1 and 2. Tumor downstaging was higher
in patients treated with UFT/FA + RT, but this result was not
statistically signiﬁcant. Nodal downstaging and loco-regional
response did not have any impact on survival or on LRC in any
group of patients.
Comparing our results with the single randomized phase III
trial7 that compared 5-FU vs. oral ﬂuoropyrimidine, we  noticed
that 3-year OS (74%) and LRC (91.1%) from oral CT group were
similar to 3-year OS (87.6%) and LRC (94.7%) that we  found,
although slightly higher in our study.
Carlos Fernandez-Martos et al. studied preoperative
CT + RT with UFT and the actuarial rate of 3-year PFS was 72%
and OS was 75%. PFS was 92% for downstaged patients and
51% for patients who had not responded (p < 0.00001). OS was
signiﬁcantly higher (p = 0.002) for patients with downstaging
following preoperative treatment than for patients who  had
not responded.13
Regarding the use of adjuvant chemotherapy after preoper-
ative treatment with chemoradiation, there is still insufﬁcient
data to allow us to draw a conclusion about its use.53,54 A
recent study showed that adjuvant CT was still of border-
line signiﬁcance (worse for adjuvant CT).47 In the EORTC
22921 trial, postoperative chemotherapy had a non-signiﬁcant
inﬂuence on local relapse and relapse free and overall
survival. Exploratory subgroup analyses suggest that only
good-prognosis patients with downstaging of cT3-4 to ypT0-
2 beneﬁt from adjuvant CT, with better PFS and OS, probably
because these patients had a disease which was responsive to
both preoperative and adjuvant treatment.55 This data sup-
ports other trials as QUASAR trial that showed a signiﬁcant
beneﬁt on survival of 3–6%.56
A recent review published by Bjuko et al. concluded that
the use of adjuvant chemotherapy in patients undergoing
preoperative radio(chemo)therapy is not evidence based and
recommended that a meta-analyses of the most relevant stud-
ies was performed, along with new trials that explore new drug
combinations vs.  observation.57
We  noticed that there was a trend for higher toxicity
incidence in the Capecitabine group than in UFT/FA group,
d rad
r
1
1
1
1
1
1
1
1
1
1
2
2
2
2382  reports of practical oncology an
although not statistically signiﬁcant (75% vs. 50%, p = 0.065).
This is probably due to the administered absolute dose which
is higher in patients treated with Capecitabine in the adju-
vant setting (2500 mg/m2/d) than in the neoadjuvant setting
(1650 mg/m2/d). In the patients treated with UFT/FA, the
administered dose was the same whether on neoadjuvant or
adjuvant setting (UFT at 300 mg/m2/d; FA at 90 mg/d).
In conclusion, we  found that there is a statistically
signiﬁcant higher pCR rate in patients treated with neoadju-
vant UFT/FA + RT than in patients treated with preoperative
Capecitabine + RT (28% vs. 10.5%, respectively, p = 0.026).
Patients with pCR from both groups had a trend to a higher
OS but we  did not observe differences in survival between the
two groups.
Compliance to neoadjuvant oral chemotherapy concomi-
tant to radiotherapy was good with no difference found in
acute toxicity or post-operative complications between both
groups.
Although these are very promising results, we need to take
into account that this study is not a randomized trial and
it might have some bias in the patients’ treatment modality
distribution that might inﬂuence some of the results.
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